
    
      Subjects receive on separate days, in random order one of the following: 1 mg BIOD-961
      intramuscularly (IM), 1 mg Lilly (IM), 1 mg Novo (IM), 1 mg BIOD-961 subcutaneously (SC), 1
      mg Lilly (SC), and 1 mg Novo (SC).
    
  